Back to News
Market Impact: 0.3
Innate Pharma Q3 Earnings Call Highlights
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
Innate Pharma initiated a Phase 3 study of its lymphoma drug lacutamab. The company also expects to present Phase 1 data for experimental cancer treatment IPH4502 on Nov. 18, in its third-quarter 2026 business update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IPHA0.55
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook